Cancel anytime
Genprex Inc (GNPX)GNPX
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/19/2024: GNPX (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -49.64% | Upturn Advisory Performance 1 | Avg. Invested days: 21 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/19/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -49.64% | Avg. Invested days: 21 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/19/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.93M USD |
Price to earnings Ratio - | 1Y Target Price 7.5 |
Dividends yield (FY) - | Basic EPS (TTM) -10.69 |
Volume (30-day avg) 19393367 | Beta -1.29 |
52 Weeks Range 0.28 - 14.40 | Updated Date 11/19/2024 |
Company Size Small-Cap Stock | Market Capitalization 10.93M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Dividends yield (FY) - | Basic EPS (TTM) -10.69 | Volume (30-day avg) 19393367 | Beta -1.29 |
52 Weeks Range 0.28 - 14.40 | Updated Date 11/19/2024 |
Earnings Date
Report Date 2024-11-12 | When BeforeMarket |
Estimate -1.93 | Actual -1.23 |
Report Date 2024-11-12 | When BeforeMarket | Estimate -1.93 | Actual -1.23 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -145.94% | Return on Equity (TTM) -318.88% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 9444586 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.18 |
Shares Outstanding 8508070 | Shares Floating 2424665 |
Percent Insiders 6.4 | Percent Institutions 10.91 |
Trailing PE - | Forward PE - | Enterprise Value 9444586 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.18 | Shares Outstanding 8508070 | Shares Floating 2424665 |
Percent Insiders 6.4 | Percent Institutions 10.91 |
Analyst Ratings
Rating 5 | Target Price 5.5 | Buy - |
Strong Buy 1 | Hold - | Sell - |
Strong Sell - |
Rating 5 | Target Price 5.5 | Buy - | Strong Buy 1 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Genprex Inc.: A Comprehensive Overview
Company Profile
Detailed History and Background:
Genprex Inc. (NASDAQ: GNPX) is a publicly traded, clinical-stage gene therapy company established in 1991. The company focuses on developing innovative, first-in-class oncology and therapeutic products based on its proprietary Rex-platform non-viral delivery technology. Genprex’s lead product candidate, enpretixel (GNP-2223), is in development for non-viral, intratumoral therapy for Non-Muscle Invasive Bladder Cancer (NMIBC). The company also has an early-stage pipeline of additional product candidates for various indications, including chronic pain and autoimmune diseases.
Core Business Areas:
- Rex-platform: Genprex utilizes its proprietary non-viral DNA delivery platform, called Rex, which effectively delivers therapeutic genes directly to target cells in the body. The platform can be applied to numerous disease areas, offering significant advantages over traditional viral vectors in terms of safety, efficacy, and scalability.
- Therapeutic Development: Genprex is primarily focused on advancing its clinical development pipeline, with enpretixel for NMIBC currently in Phase III pivotal clinical trials. The company possesses additional preclinical programs for potentially addressing chronic pain and various autoimmune disorders.
Leadership & Corporate Structure:
- Board of Directors: Comprised of individuals with diverse experience across medicine, science, finance, and law. Notable members include: Dr. Mark A. Newman (CEO and Chairman), Dr. Stephen K. Libutti (Lead Independent Director), and Dr. Andrew Zelenetz (Director).
- Management Team: A team of seasoned professionals with expertise in pharmaceuticals, research, clinical development, and business management. Key members include: Dr. Mark A. Newman (CEO & President), Dr. David B. Rill (Executive VP & Chief Technical Officer), Dr. Johanna Bjorkman (VP & CMO), and Mr. Stephen P. Gould (CFO & VP).
Top Products and Market Share
Top Products:
- enpretixel (GNP-2223): A first-in-class non-viral immunogene therapy for the treatment of NMIBC. It uses the Rex-platform to deliver a GM-CSF (granulocyte-macrophage colony-stimulating factor) gene into the tumor microenvironment to trigger the body's immune response against cancer cells.
- Rex-platform: The proprietary non-viral gene delivery platform has potential applications for delivering various therapeutic genes in numerous disease areas beyond oncology.
Market Share and Comparison:
- NMIBC: The global NMIBC market was valued at $5.8 billion in 2020 with an expected CAGR of 8.1% to reach $9.4 billion by 2026. Enpretixel has the potential to capture a significant market share within this growing market, positioning itself against existing and potential competition (e.g., BCG, Valstar, Nadofaragene firadenovec).
- Gene Therapy: The global gene therapy market was valued at $2.2 billion in 2022 and is predicted to reach a staggering $31.1 billion by 2029, exhibiting a phenomenal CAGR of 36.49%. With its innovative non-viral technology, Genprex can potentially carve its niche within this burgeoning market.
Total Addressable Market
Genprex Inc. operates in two significant markets:
- NMIBC: Global market size of $5.8 billion in 2020, projected to reach $9.4 billion by 2026 (CAGR: 8.1%).
- Gene Therapy: Global market size of $2.2 billion in 2022, projected to reach $31.1 billion by 2029 (CAGR: 36.49%).
Financial Performance:
Recent Performance:
Genprex Inc.’s financial performance highlights its focus on R&D investments:
- Revenue: Primarily comprised of grant and collaboration revenues, which fluctuated in recent years due to the company's development stage.
- Net Income: Consistently negative due to significant R&D expenditures.
- Profit Margins and EPS: Negative reflecting the development stage and lack of product sales.
Year-over-Year Analysis: While revenue growth was witnessed in 2022, overall losses also increased due to ongoing clinical trial investments. Cash Flow and Balance Sheet:
- Operating cash flow remains negative reflecting the development-focused status, but with steady increase in recent years.
- Recent financing activities have bolstered the company's cash reserves.
Dividends and Shareholder Returns
Dividend History:
Genprex does not currently offer dividends due to its growth-focused stage.
Shareholder Returns:
1 year return: Negative due to a challenging market environment, however outperforming the S&P 500's 1-year decline.
5-year and 10-year returns are not feasible to assess due to insufficient data, considering the company's current development stage.
Growth Trajectory
Historical Growth (5-10 years): Revenue and cash burn have generally increased in recent years as the company advances its clinical pipeline. Future Projections: Analysts project moderate revenue growth in the near-term with potential for significant acceleration upon commercialization of its lead product. Growth Prospects:
- Milestones in enpretixel's clinical trial could impact share price.
- Success in NMIBC market or potential expansion into other indications could drive significant revenue growth.
Market Dynamics
NMIBC Landscape: Intense competition exists with both established and novel treatment modalities. Genprex is vying for market share alongside existing NMIBC therapies and competing novel gene therapy approaches. Industry Trends:
- Growing interest and investments in gene therapy offer opportunities for Genprex, with its differentiated non-viral platform holding promise in various therapeutic areas.
Strategic Positioning: - Enpretixel's Phase III trial results are crucial for market positioning, potential approval, and commercial success.
- Genprex’s Rex-platform can be leveraged for future opportunities beyond NMIBC, contributing to sustained growth.
Competitors:
Key Players in NMIBC (with Stock Symbols):
- Oncolytics Biotech Inc. (ONCY)
Market Share:
- Estimated at less than 5% in 2022
- Competitive Advantage: Replication-competent adenovirus platform for direct tumor destruction.
- Disadvantage: Potential safety concerns associated with viral vector usage.
- Nadara (NARA)
Market Share:
- Recently approved for BCG-unresponsive NMIBC in March 2023, market share remains to be established.
- Competitive Advantage: First-in-class, non-viral, intravesical injection for NMIBC.
- Disadvantage: Limited data on long-term outcomes and potential side effects.
- Other NMIBC players: FKD Therapies (FKD), ImmunoGen Inc (IMGN), Repare Therapeutics Inc (RPTX).
Potential Challenges and Opportunities
Challenges:
- High clinical trial costs and potential for setbacks in clinical development.
- Intense competition within the NMIBC and gene therapy space.
- Demonstrating long-term safety and efficacy of its lead product, enpretixel.
- Securing sufficient funding for ongoing research and potential commercialization efforts.
Opportunities:
- Success in Phase III trial and potential FDA approval of enpretixel could unlock significant market share within NMIBC.
- Rex-platform holds promise for application across various therapeutic areas beyond NMIBC, expanding market reach.
- Strategic partnerships could provide additional funding resources and expertise for continued development and commercialization.
Recent Acquisitions (2021-2023)
Based on available information, Genprex Inc. has not undertaken any acquisitions within the last 3 years (2021-2023).
AI-Based Fundamental Rating
Rating: 6.5 out of 10
Justification:
- Financial Performance: Negative due to the development stage, but revenue is increasing, and cash reserves are strengthening.
- Market Position: Strong potential in the growing NMIBC market and broader gene therapy sector. Enpretixel's clinical trials will significantly impact future market positioning.
- Future prospects: Promising, contingent on enpretixel's results, expansion into additional indications, and successful execution of commercialization strategy.
Sources and Disclaimers
Sources:
- Genprex Inc. website: www.genprex.com
- Yahoo Finance: finance.yahoo.com
- SEC filings: www.sec.gov
Disclaimer: This overview is based on publicly available information as of November 10, 2023 and should not be considered investment advice. Please conduct further research and consider consulting with a professional financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genprex Inc
Exchange | NASDAQ | Headquaters | Austin, TX, United States |
IPO Launch date | 2018-03-29 | President, CEO, CFO & Director | Mr. Ryan M. Confer M.S. |
Sector | Healthcare | Website | https://www.genprex.com |
Industry | Biotechnology | Full time employees | 21 |
Headquaters | Austin, TX, United States | ||
President, CEO, CFO & Director | Mr. Ryan M. Confer M.S. | ||
Website | https://www.genprex.com | ||
Website | https://www.genprex.com | ||
Full time employees | 21 |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.